Kura Oncology ((KURA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Kura Oncology is conducting a Phase 1a/1b clinical trial titled A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure. The study aims to evaluate the safety, tolerability, and preliminary antitumor activity of ziftomenib combined with imatinib in patients with advanced GIST who have not responded to prior imatinib treatment, highlighting its potential significance in addressing treatment-resistant cases.
Intervention/Treatment: The study tests two drugs: ziftomenib, a menin inhibitor, and imatinib mesylate, a kinase inhibitor. These are combined to assess their effectiveness in treating advanced GIST, particularly after failure of previous imatinib therapy.
Study Design: The study is interventional, non-randomized, and follows a single-group model without masking. Its primary purpose is treatment-focused, aiming to determine the safety and efficacy of the drug combination in a controlled setting.
Study Timeline: The study began on October 14, 2024, with its latest update on September 30, 2025. These dates are crucial as they mark the progression and current status of the trial, which is still recruiting participants.
Market Implications: This study update is significant for Kura Oncology’s stock performance and investor sentiment, as successful results could enhance the company’s market position in the oncology sector. It also positions Kura against competitors in the GIST treatment landscape, potentially influencing industry dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.